Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Edwards Lifesciences Corp    EW

Delayed Quote. Delayed  - 02/17 10:02:43 pm
89.74 USD   -0.21%
02/01 EDWARDS LIFESCI : beats Street 4Q forecasts
02/01 EDWARDS LIFESCI : Reports Fourth Quarter Results
01/27EDWARDS LIFESCI : annual earnings release
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Edwards Lifesciences Corp : Edwards Lifesciences' Chairman and CEO to Exercise Stock Options Under 10b5-1 Stock Trading Plan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/01/2013 | 04:37pm CET

IRVINE, CA, March 01, 2013 -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that its chairman and chief executive officer, Michael A. Mussallem, has adopted a pre-arranged stock trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934. In May 2013, the plan will begin exercising stock options, the vast majority of which are scheduled to expire in 2014.

The plan anticipates the exercise and sale of 29,500 shares per month at market prices between May 2013 and April 2014. Rule 10b5-1 allows corporate executives to adopt stock trading plans to buy or sell shares of company stock when they are not in possession of material, non-public information. Mussallem plans to enter into similar types of trading plans each year as stock options near their expiration dates in order to spread sales evenly over an extended period of time.

Under the company's stock ownership guidelines, Mussallem is required to own shares of company stock with an aggregate market value equal to six times his base salary. At the conclusion of the plans, Mussallem will still hold shares well in excess of the number required to meet these guidelines. Transactions under these plans will be disclosed publicly through Form 144 and Form 4 filings with the U.S. Securities and Exchange Commission. The Form 4 filings will also be posted on Edwards' investor relations Web site at ir.edwards.com.

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. Additional company information can be found at edwards.com.

Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

# # #


distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EDWARDS LIFESCIENCES CORP
02/18 EDWARDS LIFESCIENCES : Federal Contracts Awarded by Federal Agencies in Iowa (Fe..
02/17 EDWARDS LIFESCIENCES : Management's Discussion and Analysis of Financial Conditi..
02/16 EDWARDS LIFESCIENCES : Patent Issued for Systems for Quickly Delivering a Prosth..
02/16 EDWARDS LIFESCIENCES : An Application for the Trademark "COMPASSION" Has Been Fi..
02/16 EDWARDS LIFESCIENCES' : Trademark Application for "QUICKDRAW" Filed
02/09 EDWARDS LIFESCIENCES : Patent Issued for Low Gradient Prosthetic Heart Valve (US..
02/09 EDWARDS LIFESCIENCES : Patent Issued for Rapid Deployment Prosthetic Heart Valve..
02/09 EDWARDS LIFESCIENCES : Trademark Application for "THERMAFIX" Filed by Edwards Li..
02/09 EDWARDS LIFESCIENCES : An Application for the Trademark "EV1000" Has Been Filed ..
02/07 EDWARDS LIFESCIENCES CORP : Other Events, Financial Statements and Exhibits (for..
More news
Sector news : Advanced Medical Equipment & Technology - NEC
02/09 Infineon, Cree warn U.S. might block Wolfspeed deal
02/02 EU probes online sales in electronics, video games, hotels
01/31DJTHERMO FISHER SCIENTIFIC : Earnings, Sales Rise
01/31DJDANAHER : Revenue, Profit Rise
01/30DJEUROPEAN MORNING BRIEFING : Corporate Events
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
02/07 INSIDERINSIGHTS.COM DAILY ROUND UP 2 : CONSOL Energy, Arconic, FNB Bancorp, Cala..
02/03 Edwards Puts A Second Mitral Valve Trial On Hold
02/02 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
02/02 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
02/02 Modest outlook sinks Edwards; shares off 7% premarket
Advertisement
Financials ($)
Sales 2017 3 257 M
EBIT 2017 973 M
Net income 2017 735 M
Finance 2017 812 M
Yield 2017 -
P/E ratio 2017 26,63
P/E ratio 2018 23,45
EV / Sales 2017 5,72x
EV / Sales 2018 5,13x
Capitalization 19 439 M
More Financials
Chart EDWARDS LIFESCIENCES CORP
Duration : Period :
Edwards Lifesciences Corp Technical Analysis Chart | EW | US28176E1082 | 4-Traders
Full-screen chart
Technical analysis trends EDWARDS LIFESCIEN...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 115 $
Spread / Average Target 28%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
Stanton J. Rowe Chief Scientific Officer & VP-Advanced Technology
John T. Cardis Independent Director
William J. Link Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
EDWARDS LIFESCIENCES C..-4.23%19 439
THERMO FISHER SCIENTIF..12.43%62 667
DANAHER CORPORATION7.98%58 138
BOSTON SCIENTIFIC CORP..17.38%34 573
INTUITIVE SURGICAL, IN..14.27%28 107
PHILIPS-4.28%27 388
More Results